The DOI matches its Crossref record.
Trial of oral miltefosine for visceral leishmaniasis
Open accessAbstract
BACKGROUND: There is no effective oral treatment for visceral leishmaniasis (kala-azar), a disseminated intracellular protozoal infection that occurs worldwide. Miltefosine, an alkyl phospholipid developed as an oral antineoplastic agent, is active against visceral infection in animal models. We tested safety, tolerance, and efficacy of miltefosine in kala-azar. METHODS: Oral doses of miltefosine were given to six groups of five Indian men for 28 days: 50 mg every second day (group 1), 100 mg every second day (group 2), 100 mg/day (group 3), 150 mg/day (group 4), 200 mg/day (group 5), and 250 mg/day (group 6). Assessment for apparent cure--taken as an afebrile state with decreased spleen size and a splenic-aspirate parasite-density score of 0--was done on days 14 and 28. Definitive cure at 8 months required a parasite-free bone-marrow aspirate and no clinical evidence of relapse. FINDINGS: 21 of 30 patients were apparently cured on day 14. Transient episodes of vomiting and diarrhoea, were common during weeks 1-2 and were seen in 22 patients. Four other patients in groups 5 and 6 had miltefosine withdrawn after 7-10 days because of vomiting. One patient in group 6 developed renal insufficiency and severe diarrhoea and died on day 21. On day 28, all 29 remaining patients were apparently cured. By 8 months, seven of ten patients in groups 1 and 2 had relapsed; however, 18 of 19 patients treated daily (groups 3-6) appeared to be cured. Among the 21 definitive cures were the four patients treated for 10 days or less and 12 for whom previous therapy with pentavalent antimony had failed. INTERPRETATION: Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Herwaldt, B. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10178-2 · Cited by 1,229
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Self-citationMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks275 · Cited by 775
Drug resistance in Indian visceral leishmaniasis
Sundar, S. (2001) · Tropical Medicine & International Health · doi:10.1046/j.1365-3156.2001.00778.x · Cited by 585
Self-citationZijlstra, E. E., & El-Hassan, A. M. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90218-4 · Cited by 494
Metadata
- Authors
- Sundar, S., Rosenkaimer, F., Makharia, M. K., Goyal, A. K., Mandal, A. K., Voss, A., Hilgard, P., & Murray, H. W.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 1998-12
- Volume
- 352
- Issue
- 9143
- Pages
- 1821-1823
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2034149848
- Cited by
- 244
- References
- 0
- FWCI
- 14.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trial of oral miltefosine for visceral leishmaniasis. https://app.cochat.ai/papers/10.1016/s0140-6736(98)04367-0
- The paper
- Sundar, S., Rosenkaimer, F., Makharia, M. K., Goyal, A. K., Mandal, A. K., Voss, A., Hilgard, P., & Murray, H. W. (1998). Trial of oral miltefosine for visceral leishmaniasis. The Lancet. https://doi.org/10.1016/s0140-6736(98)04367-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.